by Pelagobio | Jul 9, 2019 | Uncategorized
Attrition levels in drug discovery remain high, with almost 60% of candidate drugs failing during clinical development due to insufficient efficacy. These failures have costly consequences for pharmaceutical and biotech companies. As well as gaining no return on their...
